155 related articles for article (PubMed ID: 16019524)
21. Moving disease biology from the lab to the clinic.
Anderson KC
Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
[TBL] [Abstract][Full Text] [Related]
22. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells.
Ohwada C; Nakaseko C; Koizumi M; Takeuchi M; Ozawa S; Naito M; Tanaka H; Oda K; Cho R; Nishimura M; Saito Y
Eur J Haematol; 2008 Mar; 80(3):245-50. PubMed ID: 18081709
[TBL] [Abstract][Full Text] [Related]
23. Adhesion of multiple myeloma cells to the bone marrow microenvironment: implications for future therapeutic strategies.
Vidriales MB; Anderson KC
Mol Med Today; 1996 Oct; 2(10):425-31. PubMed ID: 8897437
[TBL] [Abstract][Full Text] [Related]
24. NRF2 Is One of the Players Involved in Bone Marrow Mediated Drug Resistance in Multiple Myeloma.
Yen CH; Hsiao HH
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30405034
[TBL] [Abstract][Full Text] [Related]
25. Role of the extracellular matrix proteins in the resistance of SP6.5 uveal melanoma cells toward cisplatin.
Bérubé M; Talbot M; Collin C; Paquet-Bouchard C; Germain L; Guérin SL; Petitclerc E
Int J Oncol; 2005 Feb; 26(2):405-13. PubMed ID: 15645125
[TBL] [Abstract][Full Text] [Related]
26. Role of the bone marrow microenvironment in multiple myeloma.
Roodman GD
J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
[TBL] [Abstract][Full Text] [Related]
27. Reelin promotes the adhesion and drug resistance of multiple myeloma cells via integrin β1 signaling and STAT3.
Lin L; Yan F; Zhao D; Lv M; Liang X; Dai H; Qin X; Zhang Y; Hao J; Sun X; Yin Y; Huang X; Zhang J; Lu J; Ge Q
Oncotarget; 2016 Mar; 7(9):9844-58. PubMed ID: 26848618
[TBL] [Abstract][Full Text] [Related]
28. The tumor microenvironment: focus on myeloma.
Dalton WS
Cancer Treat Rev; 2003 May; 29 Suppl 1():11-9. PubMed ID: 12738239
[TBL] [Abstract][Full Text] [Related]
29. Growth factors and antiapoptotic signaling pathways in multiple myeloma.
van de Donk NW; Lokhorst HM; Bloem AC
Leukemia; 2005 Dec; 19(12):2177-85. PubMed ID: 16239913
[TBL] [Abstract][Full Text] [Related]
30. The role of adhesion molecules in multiple myeloma.
Cook G; Dumbar M; Franklin IM
Acta Haematol; 1997; 97(1-2):81-9. PubMed ID: 8980613
[TBL] [Abstract][Full Text] [Related]
31. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
Hazlehurst LA; Enkemann SA; Beam CA; Argilagos RF; Painter J; Shain KH; Saporta S; Boulware D; Moscinski L; Alsina M; Dalton WS
Cancer Res; 2003 Nov; 63(22):7900-6. PubMed ID: 14633719
[TBL] [Abstract][Full Text] [Related]
32. Fibronectin distribution in human bone marrow stroma: matrix assembly and tumor cell adhesion via alpha5 beta1 integrin.
Van der Velde-Zimmermann D; Verdaasdonk MA; Rademakers LH; De Weger RA; Van den Tweel JG; Joling P
Exp Cell Res; 1997 Jan; 230(1):111-20. PubMed ID: 9013713
[TBL] [Abstract][Full Text] [Related]
33. Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma.
Moschetta M; Basile A; Ferrucci A; Frassanito MA; Rao L; Ria R; Solimando AG; Giuliani N; Boccarelli A; Fumarola F; Coluccia M; Rossini B; Ruggieri S; Nico B; Maiorano E; Ribatti D; Roccaro AM; Vacca A
Clin Cancer Res; 2013 Aug; 19(16):4371-82. PubMed ID: 23804425
[TBL] [Abstract][Full Text] [Related]
34. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
Grigorieva I; Thomas X; Epstein J
Exp Hematol; 1998 Jul; 26(7):597-603. PubMed ID: 9657134
[TBL] [Abstract][Full Text] [Related]
35. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.
Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Hou HA; Chou WC; Chou SC; Hsu SC; Ko BS; Lu HY; Tsay W; Tien HF
PLoS One; 2015; 10(9):e0137552. PubMed ID: 26379028
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.
Yang WC; Lin SF
Biomed Res Int; 2015; 2015():341430. PubMed ID: 26649299
[TBL] [Abstract][Full Text] [Related]
37. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
Podar K; Richardson PG; Chauhan D; Anderson KC
Expert Rev Anticancer Ther; 2007 Apr; 7(4):551-66. PubMed ID: 17428175
[TBL] [Abstract][Full Text] [Related]
38. Targeting the bone marrow microenvironment in hematologic malignancies.
Dalton WS; Hazlehurst L; Shain K; Landowski T; Alsina M
Semin Hematol; 2004 Apr; 41(2 Suppl 4):1-5. PubMed ID: 15190509
[TBL] [Abstract][Full Text] [Related]
39. Toll-like receptors in human multiple myeloma: new insight into inflammation-related pathogenesis.
Abdi J; Garssen J; Redegeld F
Curr Mol Med; 2014 May; 14(4):423-31. PubMed ID: 24730527
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
Bar-Natan M; Stroopinsky D; Luptakova K; Coll MD; Apel A; Rajabi H; Pyzer AR; Palmer K; Reagan MR; Nahas MR; Karp Leaf R; Jain S; Arnason J; Ghobrial IM; Anderson KC; Kufe D; Rosenblatt J; Avigan D
Br J Haematol; 2017 Mar; 176(6):929-938. PubMed ID: 28107546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
